Stay updated on Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial page.

Latest updates to the Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.3.2 is now shown (replacing v3.3.1) on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page revision tag was updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the site-wide notice about government funding and operating status from the page. The rest of the study details, eligibility criteria, and results information remain unchanged.SummaryDifference0.3%

- Check43 days agoChange DetectedMinor formatting tweaks and minor textual edits are evident, with no changes to core study details (objectives, endpoints, eligibility criteria, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference2%

- Check79 days agoChange DetectedExpanded page content with new immune-related terms; updated version to v3.1.0 and removal of the old v3.0.2 tag.SummaryDifference0.9%

Stay in the know with updates to Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial page.